Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SALL4 | Q9UJQ4 | 3/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | GFER | P55789 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | TRIM33 | Q9UPN9 | 3/20 | 0.57 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968891 | 0.99 | ALDH1A1 (0.61) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL13464359 | 0.91 | SALL4 (0.64) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL1965683 | 0.89 | ALDH1A1 (0.63) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL1969989 | 0.85 | ADORA1 (0.61) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL13464368 | 0.84 | ADORA1 (0.59) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL1965252 | 0.83 | ADORA1 (0.64) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL1970474 | 0.82 | ALDH1A1 (0.63) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL1965129 | 0.82 | ADORA1 (0.59) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL1965852 | 0.81 | ADORA1 (0.78) | SALL4ADORA1ALDH1A1GAAKDM4E | |
| SCHEMBL1965515 | 0.81 | SALL4 (0.64) | SALL4ADORA1ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | claimed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | claimed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | claimed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | SALL4 4454/4885ADORA1 1122/4885ALDH1A1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.